Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Treasury Shares: 2022-2025

Historic Treasury Shares for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $2.4 million.

  • Entrada Therapeutics' Treasury Shares rose 17.03% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 17.03%. This contributed to the annual value of $2.0 million for FY2024, which is 55.18% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Treasury Shares stood at $2.4 million, which was down 5.09% from $2.5 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Treasury Shares peaked at $2.7 million during Q1 2025, and registered a low of $295,104 during Q2 2022.
  • Its 3-year average for Treasury Shares is $1.8 million, with a median of $2.0 million in 2024.
  • Data for Entrada Therapeutics' Treasury Shares shows a peak YoY soared of 198.80% (in 2024) over the last 5 years.
  • Entrada Therapeutics' Treasury Shares (Quarterly) stood at $463,964 in 2022, then soared by 173.40% to $1.3 million in 2023, then spiked by 55.18% to $2.0 million in 2024, then rose by 17.03% to $2.4 million in 2025.
  • Its Treasury Shares stands at $2.4 million for Q3 2025, versus $2.5 million for Q2 2025 and $2.7 million for Q1 2025.